The mechanisms underlying the development of peripheral insulin resistance are complex.
Several studies have linked sclerostin, an osteocyte-derived inhibitor of the Wnt/β-catenin pathway, to obesity and insulin resistance. The aim of this study was to investigate 1) whether serum sclerostin is associated with insulin sensitivity in lean and/or obese women; and 2) whether hyperinsulinemia affects serum sclerostin concentrations.
A cross-sectional study.
Insulin sensitivity was measured in lean (BMI<25 kg·m-2) and obese (BMI > 30 kg·m-2) women using a hyperinsulinemic-euglycemic clamp. Serum sclerostin was measured at baseline and during the clamp procedure.
We studied 21 lean and 22 obese women with a median age of 40 and 43
years and a median BMI of 22.4 and 33.5 kg·m-2, respectively. Obese women had higher
serum sclerostin than lean women (122±33 vs 93±33 nmol/L, p<0.01). Higher serum
sclerostin was associated with lower insulin sensitivity in obese, but not in lean individuals
(difference in M value between highest and lowest quartile: -7.02 mg⋅kg−1⋅min−1, p =
0.03 and 1.59 mg⋅kg−1⋅min−1, p = 0.50, respectively). Hyperinsulinemia did not affect serum
sclerostin in lean nor obese women (p>0.5).
Serum sclerostin is negatively associated with insulin sensitivity as measured
with the hyperinsulinemic euglycemic clamp in obese, but not lean women. This indicates a potential role of the Wnt/β-catenin pathway in regulating insulin sensitivity particularly in obese individuals. Our findings remain hypothesis-generating and should be confirmed by additional studies.
If the inline PDF is not rendering correctly, you can download the PDF file here.